Patrick G. Gattari is Chair of the firm’s Licensing Practice Group.
Mr. Gattari’s clients say that they value his comprehensive and practical approach to monetizing and optimizing the asset value of intellectual property. With more than 25 years of experience as an intellectual property attorney, Mr. Gattari helps bioscience, pharmaceutical, clinical diagnostics and medical device companies build and manage robust U.S. and international patent portfolios.
Clients draw on his expertise to structure and negotiate their intellectual property transactions, including agreements related to licensing, research, collaboration, commercialization, supply and distribution. This work includes counseling and diligence related to intellectual property matters associated with financing, mergers and acquisitions.
As a trusted adviser to his clients on intellectual property matters, Mr. Gattari has prosecuted patent applications in over 50 countries and regularly counsels clients on freedom to operate, infringement, and enforcement matters, as well as disputes over IP rights.
Prior to joining MBHB, Mr. Gattari was patent counsel at Dade Behring, Inc. (now Siemens Healthcare Diagnostics). Early in his career, he worked for Abbott Laboratories in a variety of positions focusing on the development and production of pharmaceutical and clinical diagnostic products.
B.S., University of Michigan,
Cellular and Molecular Biology
J.D., Southern Methodist University Dedman School of Law
U.S. Patent & Trademark Office
University of Chicago
Lecturer, Molecular Engineering (2021-2022)
IIT Chicago-Kent College of Law
Adjunct Professor, Intellectual Property and Technology Licensing (2006-2022)
Northwestern University McCormick School of Engineering
Adjunct Professor (2001-2012)
Illinois Biotechnology Industry Organization (iBIO)
Chicago Innovation Mentors (CIM) / iBIO PROPEL® Program
Mentor/Lead Mentor for numerous start-ups
Licensing Executives Society (LES)
Former Chicago Chapter Chair
Negotiated and prepared licensing deals for dozens of early-stage and maturing companies.
Prepared and/or prosecuted thousands of patent applications in over 50 countries.
Developed and managed clinically essential, worldwide patent portfolios for therapeutic antibodies and other pharmaceuticals for global and early-stage companies.
Represented more than 10 distinct clinical diagnostic companies for a variety of platforms and technologies related to the detection of nucleic acids, peptides and small molecule markers.
Strategically advised numerous pharma, diagnostic and medical device companies to successfully evaluate and acquire or divest intellectual property assets to optimize enterprise value during mergers and acquisitions.
Advised on hundreds of IP diligence reviews for buyers, sellers, lenders and investors.
“Beyond Hybrid Licenses— Strategies for Post Patent Expiration Payments in the United States,” les Nouvelles – Journal of the Licensing Executives Society, Volume LII No. 1, March 2017.
“Patent exhaustion doctrine continues to energise the courts,” Intellectual Property Magazine, September 2014.
“Help or Havoc? A New Era of Supreme Court Interest in Biotech,” BioLogical Quarterly, Winter 2013.
“The Role of Patent Law in Incentivizing Green Technology,” Northwestern Journal of Technology and Intellectual Property, Vol. 11, No. 2, Jan. 2013.
“Maintaining Confidentiality in Technology Transactions: New Problems with an Old Concept,” 2010 Digital Guide to Intellectual Property.
“Supreme Court Weighs Patent Rights and Activities Associated With FDA Approval of New Drugs,” BioExecutive International, April 2005.
“Determining Inventorship of U.S. Patent Applications” Intellectual Property & Technology Law Journal, Vol. 17, No. 5, 2005.